OJU1.F Oramed Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
3.59 EUR
Close of Nov 13, 2026
1.84 4.53
Market cap
EUR 150M
P/E
1.0x
P/B
0.52x
ROE
53.1%
Dividend yield
5.99%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.

Is OJU1.F undervalued?

Graham number

The Graham number of Oramed Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oramed Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Oramed Pharmaceuticals Inc yet.

Oramed Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquarter…

Full company profile